Cingulate (CING) investor relations material

Company overview and business model

• Biopharmaceutical company leveraging proprietary Precision Timed Release (PTRT) drug delivery platform to develop next-generation pharmaceuticals targeting conditions with burdensome dosing and suboptimal outcomes.

• Initial focus on ADHD and anxiety, with lead candidates CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD, and CTx-2103 (buspirone) for anxiety.

• PTRT platform aims to enable true once-daily, multi-dose tablets, addressing unmet needs in current ADHD treatment paradigms.

• Seeks to reduce abuse, improve compliance, and offer economic benefits by eliminating the need for booster doses.

Financial performance and metrics

• Private placement in January 2026 raised approximately $12.0 million at $5.14 per share (including $0.10 per warrant share).

• As of April 10, 2026, 12,250,564 shares of common stock outstanding.

• Audit report for 2025 and 2024 notes substantial doubt about ability to continue as a going concern due to losses and negative cash flows from operations.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; proceeds from warrant exercises (up to $9.4 million if exercised for cash) will fund regulatory approval, development, manufacturing, commercialization of CTx-1301, working capital, capital expenditures, and R&D.

• Management has broad discretion in application of proceeds, including potential acquisitions or investments in complementary businesses or technologies.